These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Autoreactive T and B cells in nervous system diseases. Sun JB Acta Neurol Scand Suppl; 1993; 142():1-56. PubMed ID: 8382894 [TBL] [Abstract][Full Text] [Related]
4. Myasthenia gravis, a model of organ-specific autoimmune disease. Berrih-Aknin S J Autoimmun; 1995 Apr; 8(2):139-43. PubMed ID: 7612144 [TBL] [Abstract][Full Text] [Related]
5. Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status. Beecher G; Putko BN; Wagner AN; Siddiqi ZA Drugs; 2019 Mar; 79(4):353-364. PubMed ID: 30762205 [TBL] [Abstract][Full Text] [Related]
6. Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities. Rose N; Holdermann S; Callegari I; Kim H; Fruh I; Kappos L; Kuhle J; Müller M; Sanderson NSR; Derfuss T Acta Neuropathol; 2022 Nov; 144(5):1005-1025. PubMed ID: 36074148 [TBL] [Abstract][Full Text] [Related]
7. Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology. Fichtner ML; Jiang R; Bourke A; Nowak RJ; O'Connor KC Front Immunol; 2020; 11():776. PubMed ID: 32547535 [TBL] [Abstract][Full Text] [Related]
8. Thymus histology and concomitant autoimmune diseases in Japanese patients with muscle-specific receptor tyrosine kinase-antibody-positive myasthenia gravis. Nakata R; Motomura M; Masuda T; Shiraishi H; Tokuda M; Fukuda T; Ando T; Yoshimura T; Tsujihata M; Kawakami A Eur J Neurol; 2013 Sep; 20(9):1272-6. PubMed ID: 23679930 [TBL] [Abstract][Full Text] [Related]
9. Complement Inhibition in Myasthenia Gravis and Neuromyelitis Optica Spectrum Disorder. Dodig D; Genge A; Selchen D; Freedman MS Can J Neurol Sci; 2023 Mar; 50(2):165-173. PubMed ID: 34895385 [TBL] [Abstract][Full Text] [Related]
10. Disorders affecting the acetylcholine receptor: myasthenia gravis and congenital myasthenia. Vincent A J Recept Res; 1987; 7(1-4):599-616. PubMed ID: 2442386 [TBL] [Abstract][Full Text] [Related]
11. Activation of the classical complement pathway in myasthenia gravis with acetylcholine receptor antibodies. Ozawa Y; Uzawa A; Onishi Y; Yasuda M; Kojima Y; Kuwabara S Muscle Nerve; 2023 Nov; 68(5):798-804. PubMed ID: 37705312 [TBL] [Abstract][Full Text] [Related]
12. Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review. Chamberlain JL; Huda S; Whittam DH; Matiello M; Morgan BP; Jacob A J Neurol; 2021 May; 268(5):1643-1664. PubMed ID: 31482201 [TBL] [Abstract][Full Text] [Related]
13. Myasthenia gravis: the role of complement at the neuromuscular junction. Howard JF Ann N Y Acad Sci; 2018 Jan; 1412(1):113-128. PubMed ID: 29266249 [TBL] [Abstract][Full Text] [Related]
14. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum. Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917 [TBL] [Abstract][Full Text] [Related]
15. Humoral antibodies to acetylcholine receptor in patients with myasthenia gravis. Aharonov A; Abramsky O; Tarrab-Hazdai R; Fuchs S Lancet; 1975 Aug; 2(7930):340-2. PubMed ID: 51144 [TBL] [Abstract][Full Text] [Related]
16. [Antibodies in myasthenia gravis]. Eymard B Rev Neurol (Paris); 2009 Feb; 165(2):137-43. PubMed ID: 19162288 [TBL] [Abstract][Full Text] [Related]